The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Drug: loperamide     Quarter: 2016Q3

Total Drug/Injury Combinations: 303     Number of Pages: 16

DRUGNAME PT EventCount
LOPERAMIDE HYDROCHLORIDE. Incorrect drug administration duration 3 view events
LOPERAMIDE HYDROCHLORIDE. Torsade de pointes 3 view events
LOPERAMIDE HYDROCHLORIDE. Toxicity to various agents 3 view events
LOPERAMIDE HYDROCHLORIDE. Type IV hypersensitivity reaction 3 view events
LOPERAMIDE Aggression 2 view events
LOPERAMIDE Agitation 2 view events
Loperamide Angioedema 2 view events
LOPERAMIDE Aspiration 2 view events
LOPERAMIDE Brain injury 2 view events
Loperamide Brugada syndrome 2 view events
LOPERAMIDE Cardiomegaly 2 view events
LOPERAMIDE Decreased appetite 2 view events
LOPERAMIDE Disturbance in attention 2 view events
LOPERAMIDE Drug effect increased 2 view events
Loperamide Dysphagia 2 view events
LOPERAMIDE Food interaction 2 view events
LOPERAMIDE Gastrointestinal stoma output abnormal 2 view events
LOPERAMIDE Hypokalaemia 2 view events
LOPERAMIDE Mydriasis 2 view events
LOPERAMIDE Night sweats 2 view events

Total Drug/Injury Combinations: 303     Number of Pages: 16

NOTE: EventCount numbers on this page include duplicate entries from event reports. (e.g. One event has DrugX entered twice, which equals 2 on this page.) The "view events" page treats these duplicates as single entries. (e.g. The 2 entries of DrugX for a single event are counted as 1 instance.)